{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:32:52Z","timestamp":1764401572561},"reference-count":18,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Military Vaccine Agency's Medical Infectious Disease Research Program","award":["MILVAX 10-1-111"],"award-info":[{"award-number":["MILVAX 10-1-111"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.vaccine.2012.02.063","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T15:38:48Z","timestamp":1331048328000},"page":"3090-3096","source":"Crossref","is-referenced-by-count":22,"title":["Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine"],"prefix":"10.1016","volume":"30","author":[{"given":"Tabitha","family":"Woolpert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Staples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Faix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall J.","family":"Nett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga I.","family":"Kosoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad J.","family":"Biggerstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sracic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.02.063_bib0005","first-page":"331","article-title":"Japanese encephalitis vaccines","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0010","unstructured":"Centers for Disease Control and Prevention. Japanese encephalitis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-1):1\u201327."},{"key":"10.1016\/j.vaccine.2012.02.063_bib0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global frequency and incidence of Japanese encephalitis","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973\u20132008","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0025","unstructured":"Food and Drug Administration Product approval information [package insert]. IXIARO (Japanese encephalitis vaccine, inactivated, absorbed). Livingston, United Kingdom; Intercell Biomedical."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.02.063_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0264-410X(00)00038-4","article-title":"Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines","volume":"18","author":"Markoff","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0035","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0040","unstructured":"Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine \u2013 Advisory Committee on Immunization Practices, 2011. MMWR Morb Mortal Wkly Rep 2011;60:661\u20133."},{"key":"10.1016\/j.vaccine.2012.02.063_bib0045","unstructured":"Centers for Disease Control and Prevention. Update on Japanese encephalitis vaccine for children \u2013 United States, May 2011. MMWR Morb Mortal Wkly Rep 2011;60:664\u20135."},{"key":"10.1016\/j.vaccine.2012.02.063_bib0050","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/CVI.00095-09","article-title":"Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests","volume":"16","author":"Johnson","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0055","series-title":"Randomization, bootstrap and Monte Carlo methods in biology","author":"Manly","year":"2001"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/01621459.1990.10476226","article-title":"Sensitivity of two-sample permutation inferences in observational studies","volume":"85","author":"Rosenbaum","year":"1990","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0065","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0070","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: Six and 12 month results of a multicenter follow-up phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0075","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0080","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0085","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.02.063_bib0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12002708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12002708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T13:25:37Z","timestamp":1543152337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12002708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":18,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0264410X12002708"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}